Monopar Therapeutics Inc. (NASDAQ:MNPR) Stock Has Consensus Price Target of $122.00 According to Brokerages

Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) have been assigned a consensus recommendation of “Moderate Buy” from the ten ratings firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $122.00.

MNPR has been the subject of a number of analyst reports. BTIG Research lifted their target price on shares of Monopar Therapeutics from $117.00 to $133.00 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. Zacks Research cut shares of Monopar Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 13th. UBS Group set a $125.00 target price on Monopar Therapeutics in a research report on Thursday, July 23rd. Weiss Ratings restated a “sell (d-)” rating on shares of Monopar Therapeutics in a report on Friday, July 17th. Finally, Wall Street Zen cut Monopar Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday.

Insider Buying and Selling at Monopar Therapeutics

In other Monopar Therapeutics news, Director Raymond Anderson sold 3,142 shares of the business’s stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $111.77, for a total transaction of $351,181.34. Following the completion of the sale, the director owned 23,751 shares in the company, valued at approximately $2,654,649.27. The trade was a 11.68% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kim Tsuchimoto sold 4,090 shares of the company’s stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $111.39, for a total transaction of $455,585.10. Following the transaction, the director owned 7,396 shares in the company, valued at approximately $823,840.44. The trade was a 35.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 44,688 shares of company stock worth $4,023,094. Company insiders own 9.70% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in MNPR. Bank of New York Mellon Corp purchased a new stake in Monopar Therapeutics in the 2nd quarter valued at $7,124,000. Walleye Capital LLC bought a new position in Monopar Therapeutics during the 1st quarter valued at $3,458,000. Siren L.L.C. lifted its stake in Monopar Therapeutics by 27.2% during the 1st quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock valued at $14,800,000 after acquiring an additional 57,820 shares in the last quarter. Bank of America Corp DE boosted its holdings in Monopar Therapeutics by 838.2% during the 1st quarter. Bank of America Corp DE now owns 59,699 shares of the company’s stock worth $3,271,000 after acquiring an additional 53,336 shares during the last quarter. Finally, ADAR1 Capital Management LLC boosted its holdings in Monopar Therapeutics by 13.0% during the 1st quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock worth $14,480,000 after acquiring an additional 30,370 shares during the last quarter. 1.83% of the stock is currently owned by institutional investors and hedge funds.

Monopar Therapeutics Price Performance

NASDAQ:MNPR opened at $72.08 on Friday. Monopar Therapeutics has a fifty-two week low of $50.07 and a fifty-two week high of $124.82. The company has a 50 day simple moving average of $102.72 and a two-hundred day simple moving average of $83.96.

Monopar Therapeutics (NASDAQ:MNPR) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.02. As a group, equities research analysts anticipate that Monopar Therapeutics will post -2.98 earnings per share for the current year.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments and diagnostic agents for cancer. The company’s research programs are designed to address serious diseases by using targeted approaches intended to improve the effectiveness and tolerability of oncology therapies.

Monopar’s portfolio has included camsirubicin, a next-generation anthracycline being developed for patients with advanced soft tissue sarcoma. The company has also developed MNPR-101, a therapeutic and imaging platform directed at the urokinase plasminogen activator receptor (uPAR), a protein associated with various aggressive cancers.